Literature DB >> 8239619

In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii.

L Cantin1, S Chamberland.   

Abstract

By using an in vitro microassay to assess drug interaction, azithromycin combined to pyrimethamine was found more active than pyrimethamine alone against Toxoplasma gondii, and additivity between those drugs was demonstrated. Our results show that the combination of azithromycin and pyrimethamine may lead to a more rapid control of T. gondii.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8239619      PMCID： PMC188107          DOI： 10.1128/AAC.37.9.1993

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii.

Authors:  J Huskinson-Mark; F G Araujo; J S Remington
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

2.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

3.  Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii.

Authors:  F G Araujo; D R Guptill; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

4.  Inhibition of Toxoplasma gondii protein synthesis by azithromycin.

Authors:  J Blais; V Garneau; S Chamberland
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

5.  In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii.

Authors:  F G Araujo; R M Shepard; J S Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-06       Impact factor: 3.267

6.  Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis.

Authors:  F Derouin; R Almadany; F Chau; B Rouveix; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

7.  Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitro microassay.

Authors:  S Chamberland; H A Kirst; W L Current
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

8.  In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) on Toxoplasma gondii.

Authors:  H R Chang; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

9.  Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS.

Authors:  J Fernandez-Martin; C Leport; P Morlat; M C Meyohas; J P Chauvin; J L Vilde
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191
  9 in total
  7 in total

1.  Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole.

Authors:  Fernanda Karoline Vieira da Silva Torchelsen; Thaila Martins Silva; Matheus Marques Milagre; Rafael Rodrigues Silva; Levi Eduardo Soares Reis; Renata Tupinambá Branquinho; Glenda Nicioli Silva; Marta de Lana
Journal:  Parasitol Res       Date:  2020-11-24       Impact factor: 2.289

2.  Miltefosine and Benznidazole Combination Improve Anti-Trypanosoma cruzi In Vitro and In Vivo Efficacy.

Authors:  Julián Ernesto Nicolás Gulin; Margarita María Catalina Bisio; Daniela Rocco; Jaime Altcheh; María Elisa Solana; Facundo García-Bournissen
Journal:  Front Cell Infect Microbiol       Date:  2022-07-05       Impact factor: 6.073

3.  Pharmacokinetic study of azithromycin with fluconazole and cotrimoxazole (trimethoprim-sulfamethoxazole) in healthy volunteers.

Authors:  G W Amsden; G Foulds; K Thakker
Journal:  Clin Drug Investig       Date:  2000       Impact factor: 2.859

4.  Localization of azithromycin in Toxoplasma gondii-infected cells.

Authors:  J C Schwab; Y Cao; M R Slowik; K A Joiner
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

5.  Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study.

Authors:  Konstantinos Balaskas; Jean Vaudaux; Noémie Boillat-Blanco; Yan Guex-Crosier
Journal:  Med Sci Monit       Date:  2012-05

6.  Central Nervous System Toxoplasmosis in HIV Pathogenesis, Diagnosis, and Therapy.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.663

7.  A prospective randomized trial of azithromycin versus trimethoprim/sulfamethoxazole in treatment of toxoplasmic retinochoroiditis.

Authors:  Alireza Lashay; Ahmad Mirshahi; Najaf Parandin; Hamid Riazi Esfahani; Mehdi Mazloumi; Mohammad Reza Lashay; Mohammad Karim Johari; Elham Ashrafi
Journal:  J Curr Ophthalmol       Date:  2016-12-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.